NCT06322628View on ClinicalTrials.gov

A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions

Nash

Interventions

DRUG

VSA006

every 12 weeks, subcutaneous injections

DRUG

Placebo

every 12 weeks, subcutaneous injections

All Listed Sponsors

lead

Visirna Therapeutics HK Limited

INDUSTRY